| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
CNS-5161,N'-(2-chloro-5-methylsulfanyl-phenyl)-N-methyl-N-(3-methylsulfanyl-phenyl)-guanidine manufacturers
- CNS-5161
-
-
2026-07-31
- CAS:160754-76-7
- Purity:
- Supply Ability: 10g
|
| | CNS-5161,N'-(2-chloro-5-methylsulfanyl-phenyl)-N-methyl-N-(3-methylsulfanyl-phenyl)-guanidine Basic information |
| | CNS-5161,N'-(2-chloro-5-methylsulfanyl-phenyl)-N-methyl-N-(3-methylsulfanyl-phenyl)-guanidine Chemical Properties |
| Boiling point | 465.4±55.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | pka | 10.22±0.10(Predicted) |
| | CNS-5161,N'-(2-chloro-5-methylsulfanyl-phenyl)-N-methyl-N-(3-methylsulfanyl-phenyl)-guanidine Usage And Synthesis |
| Chemical Properties | Yellowish oil | | Uses | CNS-5161 is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate. | | in vivo | In the neonatal rat NMDA excitotoxicity model in vivo, CNS-5161 (CNS 5161) protects against the necrotic effects of exogenous N-methyl-D-aspartate with an ED80 of 4 mg/kg by the intraperitoneal (i.p.) route. CNS-5161 also shows a 91% inhibition of audiogenic seizures in DBA/2 mice at 4 mg/kg i.p., and has a neuroprotective effect following hypoxix/ischaemic brain injury in neonatal rats[1]. | | References | [1] Walters MR, et al. Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br J Clin Pharmacol. 2002 Mar;53(3):305-11. DOI:10.1046/j.0306-5251.2001.01541.x |
| | CNS-5161,N'-(2-chloro-5-methylsulfanyl-phenyl)-N-methyl-N-(3-methylsulfanyl-phenyl)-guanidine Preparation Products And Raw materials |
|